Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Intervention Study to Evaluate the Impact of Treating gHAT Seropositive Subjects With Acoziborole on Transmission of T.b. Gambiense, and Obtain Further Safety Data on Acoziborole in gHAT Seropositive Individuals

NCT06356974 is registered in ClinicalTrials.gov with Drugs for Neglected Diseases as lead sponsor.

NCT NCT06356974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06356974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Intervention Study to Evaluate the Impact of Treating gHAT Seropositive Subjects With Acoziborole on Transmission of T.b. Gambiense, and Obtain Further Safety Data on Acoziborole in gHAT Seropositive Individuals
Lead sponsor
Drugs for Neglected Diseases
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 8, 2024
Completion date
December 30, 2027
Enrollment
2,500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

human african trypanosomiasis